AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25504994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 50 mg twice daily for 14 days
Number of subjects: 50
Study 25504994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 100 mg twice daily for 14 days
Number of subjects: 50
Study 25504994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily for 28 days
Number of subjects: 50
Study 25504994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib added to ongoing pirfenidone therapy
Number of subjects: 50
Study 25504994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25504994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 50
Study 25504994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 50
Study 23499605 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 3025
Study 23499605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3025
Study 20135132 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg estradiol vaginal tablets (group I)
Number of subjects: 42
Study 20135132 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hyaluronic acid sodium salt vaginal tablets (group II)
Number of subjects: 42
Study 19660851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) based screening
Number of subjects: 162243
Study 19660851 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-screened)
Number of subjects: 162243
Study 16734312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop with Dyract Seal
Number of subjects: 56
Study 16734312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop with Concise
Number of subjects: 56
Study 16734312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop with Visio‐Seal
Number of subjects: 56
Study 16734312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop with Helioseal
Number of subjects: 56
Study 16734312 — intervention group
Group type: COMPARATOR
Intervention: Conventional etch with Dyract Seal
Number of subjects: 56
Study 16734312 — intervention group
Group type: COMPARATOR
Intervention: Conventional etch with Concise
Number of subjects: 56
Study 15119985 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment of meta-analyses of RCTs of pharmacotherapy for MDD
Number of subjects: 32
Study 15119985 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment using QUOROM checklist
Number of subjects: 32
Study 11402910 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg for 4 weeks
Number of subjects: 574
Study 11402910 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg for 4 weeks
Number of subjects: 574
Study 9436499 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 0
Study 8429284 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 298
Study 8429284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 3304565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with fentanyl (100 mu)
Number of subjects: 0
Study 3304565 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine without fentanyl
Number of subjects: 0
Study 31534560 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 treatment
Number of subjects: 448
Study 31534560 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 448
Study 29522710 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/d vitamin C as a twice daily bolus infusion
Number of subjects: 20
Study 29522710 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/d vitamin C as continuous infusion
Number of subjects: 20
Study 29522710 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/d vitamin C as a twice daily bolus infusion
Number of subjects: 20
Study 29522710 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/d vitamin C as continuous infusion
Number of subjects: 20
Study 29522710 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/d vitamin C (all regimens)
Number of subjects: 20
Study 29522710 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/d vitamin C (all regimens)
Number of subjects: 20
Study 29522710 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discontinuation of vitamin C
Number of subjects: 20
Study 25969567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes and guideline-based treatment according to ADA recommendations
Number of subjects: 77
Study 25969567 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 77
Study 24882434 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice daily
Number of subjects: 265
Study 24882434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 22585884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer step‐based Green Prescription
Number of subjects: 330
Study 22585884 — intervention group
Group type: COMPARATOR
Intervention: Standard Green Prescription
Number of subjects: 330
Study 22585884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 330
Study 20533635 — intervention group
Group type: EXPERIMENTAL
Intervention: All Bond 3 (BISCO, Inc)
Number of subjects: 50
Study 20533635 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond (Dentsply)
Number of subjects: 50
Study 20533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond+Alloy Primer (Kuraray)
Number of subjects: 50
Study 20533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuraray DC Bond (Kuraray)
Number of subjects: 50
Study 20533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno V (Dentsply)
Number of subjects: 50
Study 20533635 — intervention group
Group type: COMPARATOR
Intervention: Self-etch adhesives
Number of subjects: 50
Study 20533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch & rinse adhesives
Number of subjects: 50
Study 17645076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous laser radiation of blood (ILRB)
Number of subjects: 130
Study 17645076 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant drug cytoflavin
Number of subjects: 130
Study 15695307 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 109
Study 12440352 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study 12440352 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant vitamin supplementation (vitamin E 600 mg/day, vitamin C 250 mg/day, betacarotene 20 mg/day)
Number of subjects: 20536
Study 12440352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20536
Study 9921566 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (14-minute video and booklet on managing cancer pain)
Number of subjects: 36
Study 9921566 — intervention group
Group type: COMPARATOR
Intervention: Control group (pain management instructions from office staff)
Number of subjects: 36
Study 9019387 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine (15 mg/ml)
Number of subjects: 112
Study 9019387 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (5 mg/ml) + Lidocaine (10 mg/ml)
Number of subjects: 112
Study 2298903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronated position
Number of subjects: 60
Study 2298903 — intervention group
Group type: EXPERIMENTAL
Intervention: Supinated position
Number of subjects: 60
Study 2298903 — intervention group
Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 60
Study 425848 — intervention group
Group type: EXPERIMENTAL
Intervention: sar1 ala8 angiotensin II (saralasin)
Number of subjects: 12
Study 31718988 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based quality indicators (QIs) recommended in 35 of the 109 valid CPGs (32%).
Number of subjects: 109
Study 31718988 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based QIs from 11 randomly selected guidelines (5 medical societies, 1 DMG, 5 GGPO).
Number of subjects: 109
Study 31718988 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative measures of QIs.
Number of subjects: 109
Study 31718988 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality objectives for QIs.
Number of subjects: 109
Study 31718988 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of quality of care based on QIs.
Number of subjects: 109
Study 29169838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (260 mg of 2% lidocaine subcutaneously and intratesticularly 5 minutes prior to castration)
Number of subjects: 36
Study 29169838 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (0.5 mg kg−1 of meloxicam subcutaneously 30 minutes prior to castration)
Number of subjects: 36
Study 29169838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative analgesia administered)
Number of subjects: 36
Study 26512601 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon/ribavirin (P‐R) treatment
Number of subjects: 19
Study 23269286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (20mg and 150mg)
Number of subjects: 0
Study 23269286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23269286 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 0
Study 21545859 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountability
Number of subjects: 243
Study 21545859 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight
Number of subjects: 243
Study 21545859 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study 19734458 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic remineralization scheme using Portland cement/simulated body fluid with polyacrylic acid and polyvinylphosphonic acid.
Number of subjects: 0
Study 19734458 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic remineralization scheme.
Number of subjects: 0
Study 17049640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 152
Study 17049640 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 152
Study 17049640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (for AF)
Number of subjects: 152
Study 17049640 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (for AF)
Number of subjects: 152
Study 17049640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (for Af)
Number of subjects: 152
Study 17049640 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (for Af)
Number of subjects: 152
Study 15476908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin 3 mg/mL plus dexamethasone 1 mg/mL (TD)
Number of subjects: 271
Study 15476908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/mL plus neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 6000 IU/mL (DNP)
Number of subjects: 271
Study 15476908 — intervention group
Group type: COMPARATOR
Intervention: Neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 7500 IU/mL plus gramicidin 20 microg/mL (NPG)
Number of subjects: 271
Study 11902023 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 97
Study 11902023 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy group
Number of subjects: 97
Study 11902023 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 97
Study 11902023 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants (all groups)
Number of subjects: 97
Study 11902023 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 97
Study 9493884 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily inner cannula changes
Number of subjects: 60
Study 9493884 — intervention group
Group type: COMPARATOR
Intervention: No inner cannula changes
Number of subjects: 60
Study 8067499 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 60 mg or less, administered daily between 5:30 and 6:00 a.m.
Number of subjects: 33
Study 8067499 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 33
Study 8067499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3052917 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK cardioplegic solution with calcium and PGI2 analogue (OP-41483, 300 micrograms/l)
Number of subjects: 18
Study 3052917 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK cardioplegic solution with calcium (1.2 mM)
Number of subjects: 18
Study 3052917 — intervention group
Group type: COMPARATOR
Intervention: Basic GIK cardioplegic solution alone (no added calcium)
Number of subjects: 18
Study 31597806 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin gel applied post-scaling and root planing (SRP)
Number of subjects: 10
Study 31597806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no curcumin gel)
Number of subjects: 10
Study 28283490 — intervention group
Group type: EXPERIMENTAL
Intervention: GOPC medical treatment orders
Number of subjects: 0
Study 28283490 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 24625625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab monotherapy (5 or 10 mg)
Number of subjects: 2700
Study 24625625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab + NSAIDs (naproxen 500 mg twice daily or celecoxib 100 mg twice daily)
Number of subjects: 2700
Study 24625625 — intervention group
Group type: COMPARATOR
Intervention: Tanezumab (5 or 10 mg)
Number of subjects: 2700
Study 24625625 — intervention group
Group type: COMPARATOR
Intervention: Tanezumab + NSAIDs
Number of subjects: 2700
Study 23287823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative APAP (autotitrating positive airway pressure)
Number of subjects: 138
Study 23287823 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study 21982649 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (50, 150, or 300 mg every 3 months, administered subcutaneously)
Number of subjects: 17200
Study 21982649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17200
Study 19238654 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg
Number of subjects: 24
Study 19238654 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin 40 mg
Number of subjects: 24
Study 19238654 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 17174178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 75
Study 17174178 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 75
Study 12900106 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-aided consultations
Number of subjects: 68
Study 12900106 — intervention group
Group type: COMPARATOR
Intervention: Routine consultations
Number of subjects: 68
Study 10882574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced‐potency inactivated poliovirus vaccine (E‐IPV) followed by monovalent oral poliovirus vaccine (OPV, type 3 Sabin)
Number of subjects: 66
Study 10882574 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypsin‐modified E‐IPV
Number of subjects: 66
Study 8807623 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium monofluorophosphate (MFP) 13.2 mg/day + calcium (1,000 mg/day) + calcifediol (50 micrograms/day)
Number of subjects: 15
Study 8807623 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1,000 mg/day) + calcifediol (50 micrograms/day)
Number of subjects: 15
Study 8807623 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no specific therapeutic intervention for bone disease)
Number of subjects: 15
Study 1360822 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement guided by PscO2 measurements
Number of subjects: 29
Study 1360822 — intervention group
Group type: COMPARATOR
Intervention: Fluid replacement guided by clinical criteria
Number of subjects: 29
Study 6586292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha A (1 ng/ml)
Number of subjects: 8
Study 6586292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha D (1 ng/ml)
Number of subjects: 8
Study 6586292 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interferon subtypes
Number of subjects: 8
Study 31256445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascaris infection
Number of subjects: 1658
Study 31256445 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing prevalence
Number of subjects: 1658
Study 31256445 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1, Th2, and CD4 + CD25 + CD127low cells
Number of subjects: 1658
Study 27933460 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening barriers counseling call conducted by a lay health advisor (LHA) using an open-ended question to identify barriers without probes.
Number of subjects: 109
Study 27933460 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening barriers counseling call conducted by a lay health advisor (LHA) using a list of potential screening barriers with probes.
Number of subjects: 109
Study 27933460 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 109
Study 27117223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 2000 ml/h
Number of subjects: 300
Study 27117223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 1000 ml/h
Number of subjects: 300
Study 27117223 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion at 500 ml/h
Number of subjects: 300
Study 24018351 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound with modified Seldinger technique (BUMST)
Number of subjects: 100
Study 22192338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 10744
Study 22192338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10744
Study 22192338 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate weight loss (3-10 kg)
Number of subjects: 10744
Study 22192338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine and Placebo
Number of subjects: 10744
Study 20061913 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid avoidance or withdrawal (SAW)
Number of subjects: 5637
Study 18030112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh botulinum toxin
Number of subjects: 45
Study 18030112 — intervention group
Group type: COMPARATOR
Intervention: Refrigerated botulinum toxin
Number of subjects: 45
Study 16051709 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean of systolic and diastolic aortic pressures
Number of subjects: 139
Study 16051709 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical formulas for MAP estimation
Number of subjects: 139
Study 16051709 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 139
Study 11973410 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 69
Study 11973410 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 69
Study 11973410 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (sublingual administration)
Number of subjects: 69
Study 11973410 — intervention group
Group type: COMPARATOR
Intervention: NG‐monomethyl‐l‐arginine (infusion)
Number of subjects: 69
Study 10962387 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy + ranitidine (n = 180)
Number of subjects: 343
Study 10962387 — intervention group
Group type: COMPARATOR
Intervention: triple therapy alone (n = 163)
Number of subjects: 343
Study 10962387 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy + ranitidine
Number of subjects: 343
Study 10962387 — intervention group
Group type: COMPARATOR
Intervention: triple therapy alone
Number of subjects: 343
Study 10962387 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication achieved
Number of subjects: 343
Study 10962387 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication failed
Number of subjects: 343
Study 8987446 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% erythromycin gel
Number of subjects: 2
Study 8987446 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 2
Study 1600584 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 micrograms yeast-derived hepatitis B vaccine
Number of subjects: 122
Study 1600584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 micrograms yeast-derived hepatitis B vaccine
Number of subjects: 122
Study 1600584 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms yeast-derived hepatitis B vaccine
Number of subjects: 122
Study 1600584 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 micrograms yeast-derived hepatitis B vaccine
Number of subjects: 122
Study 1600584 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages of yeast-derived hepatitis B vaccine
Number of subjects: 122
Study 6230611 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic infusion controller (IVAC 230)
Number of subjects: 0
Study 6230611 — intervention group
Group type: COMPARATOR
Intervention: Standard infusion method (control group)
Number of subjects: 0
Study 29236550 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette advertisements (n=352)
Number of subjects: 802
Study 29236550 — intervention group
Group type: COMPARATOR
Intervention: Control advertisements (n=320)
Number of subjects: 802
Study 29236550 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette advertisements (current smokers, n=31)
Number of subjects: 802
Study 29236550 — intervention group
Group type: COMPARATOR
Intervention: Control advertisements (current smokers, n=31)
Number of subjects: 802
Study 29526749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of Oxytocin
Number of subjects: 60
Study 29526749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27356705 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training based on the Health Belief Model (HBM)
Number of subjects: 330
Study 27356705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 330
Study 25445613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lantigen B (TG)
Number of subjects: 120